


Hawaii Memory Center & Alzheimer's Research Unit selected to Investigate Phase 1b study evaluating NMRA-511 for Treatment of Agitation Associated with Alzheimer's Dementia August 2024 Honolulu



Agitation is one of the most disruptive and burdensome symptoms for individuals and their families as it is associated with greater caregiver stress, increased morbidity and mortality, and earlier placement in long-term care facilities. Despite the significant impact of agitation in AD, there is currently only one approved product available, which carries a black-box warning for mortality in elderly people.

According to [Neuroma website](#), NMRA-511 is an oral, highly potent and selective antagonist of the vasopressin 1a receptor (V1aR) and is highly brain penetrant. Modulation of the V1aR is known to play a role in the regulation of aggression, stress and anxiety responses.

Phase 1b study is a multicenter, randomized, double-blind, placebo-controlled, parallel-group cohort designed to evaluate the safety, tolerability, and efficacy of NMRA-511 20 mg twice-daily (BID) in approximately 88 people with agitation associated with dementia due to AD. Eligible patients include:

- 55 to 90 years
- Diagnosis of Alzheimer's dementia
- Agitation
- Mini-Mental State Examination (MMSE) score 5 - 24



"Our Hawaii patients, caregivers, families, neurologists & researchers are honored to contribute to the development of Novel Alzheimer's Therapy" Kore Kai Liow, MD, Neurologist & Principal Investigator, [Hawaii Memory Disorders Center](#) & [Alzheimer's Research Unit](#), Clinical Professor of Medicine (Neurology), Graduate Faculty, Clinical & Translational Research, University of Hawai'i John Burns School of Medicine.

Dedicated Hawaii Alzheimer's Research Hotline (808) 564-6141